TWO TOWER PLACE, SOUTH SAN FRANCISCO, CA
Amended material disclosure
Reports Second Quarter 2026 Financial Results and Recent Updates
Amendment Approved to 2018 Stock Incentive Plan Increasing Shares to 2.68M
Announces the Closing of its Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
Announces Expansion of ABI-6250 Clinical Development Into Cholestatic Liver Diseases
Reports First Quarter 2026 Financial Results and Recent Highlights
Annual Report to Security Holders
Assembly Biosciences Announces 2026 Corporate Bonus Plan Approval
Q2
Q1
FY 2025
Q3
FY 2024
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload